Esophageal cancer with eyeball metastasis is scarce,and the clinical diagnosis is based on ul-trasound.The treatment method is surgical removal at present.Our focus is through other local or systemic treat-ment to protect eyeball,protect the integrity intact and facial appearance.One patient's clinical data with esopha-geal eyeball metastasis from the People′s Liberation Army Cancer Center of No.105 Hospital was included.The patient was completed“enucleation of the right side of eyeball” by ultrasound diagnosis.The results of pathologi-cal suggested that poorly differentiated squamous cell carcinoma metastasis in the eye.Eyeball metastases′s opera-tion was received a good recovery after 2 months and there was no recurrence.In the present paper,we discuss e-sophageal eyeball metastases clinical characteristics and methods of diagnosis and treatment combined with the lit-erature.

Lung squamous cell carcinoma (LSCC) accounts for approximately 30% of non-small cell lung cancer (NSCLC) cases and is the second most common histological type of lung cancer. Anaplastic lymphoma kinase (ALK)-positive NSCLC accounts for only 2%-5% of all NSCLC cases, and is almost exclusively detected in patients with lung adenocarcinoma. Thus, ALK testing is not routinely performed in the LSCC population, and the efficacy of such treatment for ALK-rearranged LSCC remains unknown. Echinoderm microtubule associated protein like 4 (EML4)-ALK (V1) and TP53 co-mutations were identified by next generation sequencing (NGS) in this patient with advanced LSCC. On December 3, 2020, Ensatinib was taken orally and the efficacy was evaluated as partial response (PR). The progression-free survival (PFS) was 19 months. When the disease progressed, the medication was changed to Loratinib. To our knowledge, Enshatinib created the longest PFS of ALK-mutant LSCC patients treated with targeted therapy since literature review. Herein, we described one case treated by Enshatinib involving a patient with both EML4-ALK and TP53 positive LSCC, and the relevant literatures were reviewed for discussing the treatment of this rare disease.
.
Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy* ; Lung Neoplasms/pathology* ; Anaplastic Lymphoma Kinase/metabolism* ; Carcinoma, Squamous Cell/genetics* ; Mutation ; Cytoskeletal Proteins/genetics* ; Lung/pathology* ; Oncogene Proteins, Fusion/genetics* ; Protein Kinase Inhibitors/therapeutic use* ; Tumor Suppressor Protein p53/genetics*